Organigram FY2024 EPS Forecast Lifted by Atb Cap Markets

Organigram Holdings Inc. (NASDAQ:OGI) – Investment analysts at Atb Cap Markets upped their FY2024 EPS estimates for shares of Organigram in a note issued to investors on Sunday, December 8th. Atb Cap Markets analyst F. Gomes now expects that the company will post earnings of ($0.23) per share for the year, up from their previous estimate of ($0.25). The consensus estimate for Organigram’s current full-year earnings is ($0.21) per share.

Organigram Stock Down 0.7 %

Organigram stock opened at $1.51 on Wednesday. The company’s fifty day simple moving average is $1.64 and its 200-day simple moving average is $1.68. Organigram has a 12 month low of $1.20 and a 12 month high of $2.91. The stock has a market cap of $164.46 million, a P/E ratio of -3.60 and a beta of 1.02.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Toronto Dominion Bank raised its position in shares of Organigram by 803.7% during the third quarter. Toronto Dominion Bank now owns 16,727 shares of the company’s stock valued at $30,000 after buying an additional 14,876 shares during the last quarter. Clear Harbor Asset Management LLC bought a new stake in Organigram in the second quarter valued at about $51,000. Canton Hathaway LLC increased its stake in Organigram by 115.8% in the second quarter. Canton Hathaway LLC now owns 41,000 shares of the company’s stock valued at $63,000 after acquiring an additional 22,000 shares during the period. Baader Bank Aktiengesellschaft increased its stake in Organigram by 26.4% in the second quarter. Baader Bank Aktiengesellschaft now owns 252,852 shares of the company’s stock valued at $388,000 after acquiring an additional 52,852 shares during the period. Finally, Renaissance Technologies LLC increased its stake in Organigram by 40.8% in the second quarter. Renaissance Technologies LLC now owns 816,948 shares of the company’s stock valued at $1,258,000 after acquiring an additional 236,700 shares during the period. Institutional investors and hedge funds own 34.63% of the company’s stock.

About Organigram

Organigram Holdings Inc, through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co, Edison JOLTS, Tremblant, and Laurentian brands.